TABLE. Clinical follow up with visceral leishmaniasis patients refractory and responsive to antimony treatment.
| Isolate | Year | Circumstances of sampling | Treatment | Clinical follow-up | SbIII IC50 ± SD μM |
|---|---|---|---|---|---|
| SbS Isolate 1 | 2009 | First episode | Meglumine | Improvement | 253.3 ± 19.1 |
| SbS Isolate 2 | 2009 | First episode | Meglumine | Improvement | 146.4 ± 24.9 |
| SbR Isolate 1 | 2009 | 6th relapse | Meglumine | Partial improvement | 804.2 ± 193,7* |
| SbR Isolate 2 | 2010 | 3th relapse | Meglumine | Partial improvement | 752.3 ± 126.4* |
Selected strains for studies: two isolates from antimony responsive patients (in vitro antimony sensitive isolates, SbS) and two from antimony refractory patients (in vitro antimony resistant isolates, SbR). IC50 previously determined after promastigote exposition to increasing concentrations of SbIII in vitro. Significant differences were determined using Student's t-test
*
(p < 0.001).